Selank

Description

Overview

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) originally designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized analogue of the C-terminal fragment of tuftsin. The native tuftsin motif is extended with a Pro-Gly-Pro sequence, a modification intended to slow enzymatic degradation and prolong the molecule’s presence in experimental systems. This material is supplied strictly for in-vitro and preclinical laboratory research and is not intended for human or animal administration, diagnostic use, or any therapeutic application.

• Class: short-chain regulatory peptide (tuftsin-derived heptapeptide)
• Common research alias: TP-7
• Format: lyophilised powder for laboratory reconstitution
• Intended context: bench research, receptor-binding assays, and preclinical model systems only

Research Context

Selank has been characterised across a body of published preclinical literature, predominantly using rodent model systems. Investigators have studied it as a reference tool compound in experiments examining anxiolytic-related behaviour, stress-response pathways, and neuropeptide signalling. Reported study designs include elevated plus maze and social interaction paradigms, unpredictable chronic mild stress protocols, and models of ethanol-withdrawal-associated behaviour, always within controlled laboratory settings and animal-model frameworks.

Because Selank is a stabilized tuftsin fragment, researchers have also examined it in the context of immunomodulatory and gene-expression endpoints, including changes in cytokine and chemokine transcript levels. These investigations position Selank as a probe for studying peptide-mediated modulation of both central and peripheral signalling in experimental preparations. G Peptide Labs supplies Selank so that qualified laboratories can reproduce, extend, or reference this literature under appropriate institutional oversight.

Mechanism of Interest

Published preclinical work has proposed several molecular avenues of interest for researchers, none of which imply any human effect. In radioligand-receptor studies, Selank has been reported to influence [3H]GABA binding, behaving as a positive allosteric modulator of GABAergic transmission in the model systems examined. Investigators have described subtype-selective, concentration-dependent modulation rather than direct receptor agonism.

• Reported interaction with GABA-A receptor binding in in-vitro assays
• Observed interplay with benzodiazepine reference compounds (e.g. diazepam) in animal-model and binding studies
• Documented effects on cytokine/chemokine gene expression in preclinical preparations
• Enzymatic-stability profile of interest for peptide-degradation and pharmacokinetic modelling

These mechanisms are described here only to summarise the existing research record and to help investigators design in-vitro and preclinical experiments. They are not statements of clinical activity.

Specifications

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH)
• Molecular formula: C33H57N11O9
• Molecular weight: approximately 751.9 g/mol
• CAS number: 129954-34-3
• PubChem CID: 11765600
• Appearance: white lyophilised powder
• Purity: 99%+ as determined by HPLC, confirmed by mass spectrometry on the accompanying certificate of analysis

Handling / Reconstitution / Storage

Handling should follow standard laboratory practice for research peptides, including the use of gloves, controlled workspaces, and analytical-grade solvents. The following guidance applies to bench preparation only.

• Storage of lyophilised powder: keep sealed at -20 degrees C, protected from light and moisture, for long-term stability.
• Reconstitution: dissolve in sterile bacteriostatic or ultrapure water for laboratory use; Selank is water-soluble and does not typically require acidic co-solvents.
• Reconstituted solution: aliquot to minimise freeze-thaw cycles and store at -20 degrees C; short-term working stocks may be held at 2-8 degrees C.
• Bring vials to room temperature before opening to reduce condensation, and record lot and reconstitution details for reproducibility.

Quality & Verification

Every lot of Selank is accompanied by a third-party certificate of analysis (COA). The COA reports the HPLC purity chromatogram and the mass-spectrometry identity confirmation, allowing researchers to verify that the material matches the stated sequence and purity before use. G Peptide Labs is a Canadian research-peptide supplier, and orders ship domestically within Canada with lot-level traceability.

• Independent HPLC purity verification (99%+)
• Mass-spectrometry identity confirmation against the expected molecular weight
• Lot-specific documentation for audit and reproducibility
• Research-use-only material; not for human or veterinary use

Selected Research

Peer-reviewed references provided for scientific context; they describe laboratory and preclinical findings only.

1. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bulletin of Experimental Biology and Medicine Kolik LG, Nadorova AV, Kozlovskaya MM, 2014. PMID: 24913576
2. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein & Peptide Letters Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N, 2018. PMID: 30255741
3. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M, 2017. PMID: 28280289